Correspondingly, decreased REDD1 expression and a signature of REDD1 loss predict poor outcomes selectively in RAS mutant but not RAS wild-type human lung and pancreas carcinomas. This evidence concerns the gene DDIT4 and exocrine pancreatic carcinoma.